Zoledronic acid-induced orbital inflammation: A case report

Zoledronic acid (ZA), a bisphosphonate (BP), is a synthetic analogue of the intrinsic bone mineralisation regulator widely used in various bone disorders. Orbital inflammation is a rare adverse effect of ZA. Among reported adverse events, approximately 2% (3474) of cases involve ocular disorders, with only about 130 cases of eye inflammation documented worldwide. We report the case of a 59-year-old male patient diagnosed with multiple myeloma who had an acute onset of orbital inflammation within 24 h of ZA infusion. The patient was managed with intravenous and topical steroids and eye drops. In general, BPs are safe and well-tolerated; however, early identification and patient education about potential side effects can help minimise risks and improve outcomes.